Endocannabinoids Part I: Molecular basis of endocannabinoid formation, action and inactivation and development of selective inhibitors

Bibliography

• MECHOULAM R: The pharmacohistory of Cannabis sativa. In: Cannabinoids as Therapeutic Agents. R Mechoulam (Ed.), Boca Raton: CRS Press (1986) pp. 1–19.
   Google Scholar
• ••A history of four millennia of medicinal use of Cannabis.
   Google Scholar
• GAONI Y AND MECHOULAM R: Isolation, structure and partial synthesis of an active constituent of hashish. J Am. Chem. Soc. (1964) 86:1646–1647.
   Web of Science ®Google Scholar
• ••The first report of the chemical structure of THC.
   Google Scholar
• MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346:561–564.
   PubMed Web of Science ®Google Scholar
• ••The first report of the molecular characterisation of acannabinoid receptor.
   Google Scholar
• MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabi-noids. Nature (1993) 365, 61–65.
   PubMed Web of Science ®Google Scholar
• ••The first report of the molecular characterisation of cannabi-noid receptor Type 2.
   Google Scholar
• MARMOR JB: Medical marijuana. West J. Med. (1998) 168:540–543.
   PubMedGoogle Scholar
• DI MARZO V, BISOGNO T AND DE PETROCELLIS L: Endocannabinoids: new targets for drug develop-ment. Curr. Pharm. Des. (2000) 6:1361–1380.
   PubMedGoogle Scholar
• •One of the most recent and comprehensive reviews on endocannabinoids and drug development.
   Google Scholar
• PERTWEE RG: Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin. Investig. Drugs (2000) 9:1553–1571.
   PubMed Web of Science ®Google Scholar
• ••A recent, comprehensive update of the possible therapeu-tical applications of cannabinoid receptor ligands and more.
   Google Scholar
• MECHOULAM R: Recent advantages in cannabinoid research. Forsch Komplementarmed (1999) 6:16–20.
   PubMedGoogle Scholar
• PAROLARO D: Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci. (1999) 65:637–644.
   PubMed Web of Science ®Google Scholar
• KLEIN TW, LANE B, NEWTON CA, FRIEDMAN H: The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med. (2000) 225:1–8.
   PubMed Web of Science ®Google Scholar
• DEVANE WA, HANUS L, BREUER A et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946–1949.
   PubMed Web of Science ®Google Scholar
• ••The first report of the characterisation of an endogenouscannabinoid receptor ligand.
   Google Scholar
• MECHOULAM R, BEN-SHABAT S, HANUS L et al: Identifi- cation of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol (1995) 50:83–90.
   PubMed Web of Science ®Google Scholar
• ••One of the two first reports of the cannabimimetic proper-ties of 2-arachidonoylglycerol.
   Google Scholar
• SUGIURA T, KONDO S, SUKAGAWA A et al.: 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. (1995) 215:89–97.
   PubMed Web of Science ®Google Scholar
• ••One of the two first reports of the cannabimimetic proper-ties of 2-arachidonoylglycerol.
   Google Scholar
• DI MARZO V, FONTANA A: Anandamide, an endoge- nous cannabimimetic eicosanoid: 'killing two birds with a stone'. Prostaglandins Leukot. Essent. Fatty Acids (1995) 53:1–11.
   PubMed Web of Science ®Google Scholar
• •The article on endogenous cannabinoids where the word 'endocannabinoid' was first proposed.
   Google Scholar
• SCHMID HHO, SCHMID PC, NATARAJAN V: N-acylated glycerophospholipids and their derivatives. Prog. Lipid Res. (1990) 29:1–43.
   PubMed Web of Science ®Google Scholar
• ••A very comprehensive review of the metabolism andpharmacology of N-acyl-ethanolamines until 1990.
   Google Scholar
• CRAVATT BF, PROSPERO-GARCIA O, SIUZDAK G et al: Chemical characterization of a family of brain lipids that induce sleep. Science (1995) 268:1506–1509.
   PubMed Web of Science ®Google Scholar
• ••The first report of the isolation and complete characterisa-tion of oleamide
   Google Scholar
• LAMBERT DM, DI MARZO V: The palmitoylethanola- mide and oleamide enigmas: are these two fatty acid amides cannabimimetic? CUIT. Med. Chem. (1999) 6:757–773.
   Web of Science ®Google Scholar
• •The only review available to date on both palmitoylethano-lamide and oleamide.
   Google Scholar
• SHESKIN T, HANUS L, SLAGER J, VOGEL Z, MECHOULAM R: Structural requirements for binding of anandamide-type compounds to the brain cannabi-noid receptor. J. Med. Chem. (1997) 40:659–667.
   PubMed Web of Science ®Google Scholar
• •A comprehensive structure-activity study on anandamide.
   Google Scholar
• HANUS L, ABU-LAFI S, FRIDE E et al.: 2-Arachidonoyl Glyceryl Ether, a novel endogenous agonist of the CB1 cannabinoid receptor. Proc. Natl. Acad. Sci. USA (2001) in press.
   Google Scholar
• ••The first report of noladin ether as an endocannabinoid.
   Google Scholar
• PERTWEE RG: Pharmacology of cannabinoid CBI. and CB2 receptors. Pharmacol. Ther. (1997) 74:129–180.
   PubMed Web of Science ®Google Scholar
• ••A very comprehensive review on the molecular pharma-cology of cannabinoid receptor ligands.
   Google Scholar
• HERKENHAM M, LYNN AB, LITTLE MD et al.: Cannabi- noid receptor localization in brain. Proc. Natl. Acad. Sci. USA (1990) 87:1932–1936.
   PubMed Web of Science ®Google Scholar
• ••The first report of CB1 receptor localisation in brain.
   Google Scholar
• FARQUHAR-SMITH WP, EGERTOVA M, BRADBURY EJ, MCMAHON SB, RICE AS, ELPHICK MR: Cannabinoid CB(1) receptor expression in rat spinal cord. Mol. Cell Neurosci. (2000) 15:510–521.
   PubMed Web of Science ®Google Scholar
• •An important report on the co-localisation of CBI receptors with VR1 vaniloiid receptors.
   Google Scholar
• WAGNER JA, VARGA K, KUNOS G: Cardiovascular actions of cannabinoids and their generation during shock. J. Mol. Med. (1998) 76:824–836.
   PubMed Web of Science ®Google Scholar
• •A review on the cardiovascular function of endocannabinoids.
   Google Scholar
• PERTWEE RG: Evidence for the presence of CB1cannabinoid receptors on peripheral neurones and for the existence of neuronal non-C131 cannabinoid receptors. Life Sci. (1999) 65:597–605.
   PubMed Web of Science ®Google Scholar
• PARIA BC, DEY SK: ligand-receptor signaling withendocannabinoids in preimplantation embryo development and implantation. Chem. Phys. Lipids (2000) 108:211–220.
   PubMed Web of Science ®Google Scholar
• •A review of one of the possible roles of endocannabinoids in reproduction.
   Google Scholar
• HILLARD CJ: Endocannabinoids and vascular function.J. Pharmacol Exp. Ther. (2000) 294:27–32.
   PubMed Web of Science ®Google Scholar
• •A review on the cardiovascular function of endocannabinoids.
   Google Scholar
• KAMINSKI NE: Regulation of the cAMP cascade, geneexpression and immune function by cannabinoid receptors. J. Neuroimmunol. (1998) 83:124–132.
   PubMed Web of Science ®Google Scholar
• DEUTSCH DG, GOLIGORSKY MS, SCHMID PC et al.Production and physiological actions of anandamide in the vasculature of the rat kidney. J. an. Invest. (1997) 100:1538–1546.
   Google Scholar
• CALIGNANO A, KATONA I, DESARNAUD F et al: Bidirec-tional control of airway responsiveness by endoge-nous cannabinoids. Nature (2000) 408:96–101.
   PubMed Web of Science ®Google Scholar
• PUFFENBARGER RA, BOOTHE AC, CABRAL GA: Cannabi-noids inhibit LPS-inducible cytokine mRNA expres-sion in rat microglial cells. Gila (2000) 29:58–69.
   PubMed Web of Science ®Google Scholar
• LEDENT C, VALVERDE O, COSSU G et al.: Unresponsive- ness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (1999) 283:401–404.
   PubMed Web of Science ®Google Scholar
• •The first report of the development of CBI receptor knockout mice.
   Google Scholar
• ZIMMER A, ZIMMER AM, HOHMANN AG, HERKENHAM M,BONNER TI: Increased mortality, hypoactivity and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. ScL USA (1999) 96:5780–5785.
   PubMed Web of Science ®Google Scholar
• BUCKLEY NE, MCCOY KL, MEZEY E et al: Irnmunomodu-lation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. (2000) 396:141–149.
   PubMed Web of Science ®Google Scholar
• •The first report of the development of CB2 receptor knockout mice.
   Google Scholar
• DI MARZO V, BREIVOGEL CS, TAO Q et al: levels, metabolism and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-GB(1), non-GB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem. (2000) 75:2434–2444.
   PubMed Web of Science ®Google Scholar
• •The first examination of anandamide pharmacology in CBI receptor knockout mice.
   Google Scholar
• DI MARZO V: `Endocannabinoids' and other fatty acidderivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta (1998) 1392:153–175.
   PubMed Web of Science ®Google Scholar
• SAGAN S, VENANCE L, TORRENS Y, CORDIER J,GLOWINSKI J, GIAUME C: Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur. NeuroscL (1999) 11:691–699.
   PubMed Web of Science ®Google Scholar
• BREIVOGEL CS, GRIFFIN G, DI MARZO V, MARTIN BR:Evidence for a new G-protein-coupled cannabinoid receptor in mouse brain. Submitted.
   Google Scholar
• JARAI Z, WAGNER JA, VARGA K et al: Cannabinoid-induced mesenteric vasodilation through an endothe-lial site distinct from CBI. or CB2 receptors. Proc. Natl. Acad. Sci. USA (1999) 96:14136–14141.
   Google Scholar
• •The first report of non-CB1, non-CB2 cannabinoid receptors in endothelial cells.
   Google Scholar
• ZYGMUNT PM, PETERSSON J, ANDERSSON DA et al: Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature (1999) 400:452–457.
   PubMed Web of Science ®Google Scholar
• ••The first report of anandamide as an agonist of rat vanilloidreceptors.
   Google Scholar
• SZALLASI A, BLUMBERG PM: Vanilloid (Capsaicin)receptors and mechanisms. Pharmacol. Rev. (1999) 51:159–212.
   PubMed Web of Science ®Google Scholar
• MEZEY E, TOTH ZE, CORTRIGHT DN et al.: Distribution of mRNA for vanilloid receptor subtype 1 (VR1) and immunoreactivity, in the central nervous system of the rat and human. Proc. Natl. Acad. ScL USA (2000) 97:3655–3660.
   PubMed Web of Science ®Google Scholar
• ••Definitive evidence of VR1 vanilloid receptors in the CNS.
   Google Scholar
• SMART D, GUNTHORPE MJ, JERMAN JC et al.: The endoge- nous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J Pharmacol (2000) 129:227–230.
   PubMed Web of Science ®Google Scholar
• •Evidence that anandamide is a full agonist of human VR1 receptors.
   Google Scholar
• ROSS RA, GIBSON TM, BROCKIE HC et al.: Structure-activity relationship for the endogenous cannabinoid, anandamide and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br. J Pharmacol (2001) 132:631–640
   PubMed Web of Science ®Google Scholar
• MACCARRONE M, LORENZON T, BARI M, MELINO G ANDFINAZZI-AGRO A: Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. (2000) 275:31938–31945.
   PubMed Web of Science ®Google Scholar
• TOGNETTO M, AMADESI S, HARRISON S et al.:Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 (VR-1) activation. J. NeuroscL (2001) 21:1104–1109.
   PubMed Web of Science ®Google Scholar
• MELCK D, BISOGNO T, DE PETROCELLIS L et al.: Unsatu-rated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem. Biophys. Res. Commun. (1999) 262:275–284.
   Google Scholar
• •Development of the CBI/VR1 receptor 'hybrid' ligand concept.
   Google Scholar
• DI MARZO V, BREIVOGEL C, BISOGNO T et al.: Neurobe-havioral activity in mice of N-vanillyl-arachidonyl-amide. Eur. j Pharmacol. (2000) 406:363–374.
   PubMed Web of Science ®Google Scholar
• SZOLCSANYI J: Anandamide and the question of its functional role for activation of capsaicin receptors. Trends Pharmacol ScL (2000) 21:203–204.
   PubMed Web of Science ®Google Scholar
• PREMKUMAR LS, AHERN GP: Induction of vanilloid receptor channel activity by protein kinase C. Nature (2000) 408:985–990.
   PubMed Web of Science ®Google Scholar
• ••An important insight into the possible regulation ofVR1-mediated actions.
   Google Scholar
• DE PETROCELLIS L, BISOGNO T, MACCARRONE M, DAVIS JB, FINAZZI-AGRO A, DI MARZO V: The activity of anandamide at vanilloid VR1 receptors requires facili-tated transport across the cell membrane and is limited by intracellular metabolism. J Biol. Chem. (2001) in press.
   Google Scholar
• HOWLETT AC: Pharmacology of cannabinoid receptors. Ann. Rev. Pharmacol. ToxicoL (1995) 35:607–634.
   PubMed Web of Science ®Google Scholar
• HOWLETT AC AND MUKHOPADHYAY S: Cellular signal transductionbyanandamideand2-arachidonoylglycerol. Chem. Phys. Lipids (2000) 108:53–70.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of the signal transduction pathways coupled to endocannabinoid signalling.
   Google Scholar
• MELCK D, RUEDA D, GALVE-ROPERH I, DE PETROCELLIS L, GUZMAN M, DI MARZO V: Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett. (1999) 463:235–240.
   PubMed Web of Science ®Google Scholar
• BOUABOULA M, POINOT-CHAZEL C, BOURRIE B et al:Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CBi. Biochem. J. (1995) 312:637–641.
   PubMed Web of Science ®Google Scholar
• GALVE-ROPERH I, SANCHEZ C, CORTES ML, DEL PULGAR TG, IZQUIERDO M, GUZMAN M: Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and ex tracellular signal-regulated kinase activation. Nature Med. (2000) 6:313–319.
   PubMed Web of Science ®Google Scholar
• ••The first report of cannabinoid antitumour activity in viva
   Google Scholar
• RUEDA D, GALVE-ROPERH I, HARO A, GUZMAN M: TheCB(1) cannabinoid receptor is coupled to the activa-tion of c-Jun N-terminal kinase. Mol. Pharmacol. (2000) 58:814–820.
   PubMed Web of Science ®Google Scholar
• SUGIURA T, KONDO S, KISHIMOTO S et al: Evidence that2-arachidonoylglycerolbutnotN-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol. Chem. (2000) 275:605–612.
   Google Scholar
• SUGIURA T, KODAKA T, NAKANE S et al: Evidence thatthe cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues and related compounds. J Biol. Chem. (1999) 274:2794–2801.
   Google Scholar
• NETZEBAND JG, CONROY SM, PARSONS KL, GRUOL DL: Can n abin o ids enhance NMDA-elicited Ca2+ signals in cerebellar granule neurons in culture. J Neurosci. (1999) 19:8765–8777.
   PubMed Web of Science ®Google Scholar
• HENRY DJ, CHAVKIN C: Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci. Lett. (1995) 186:91–94.
   PubMed Web of Science ®Google Scholar
• GLASS M, FELDER CC: Concurrent stimulation ofcannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CBI. receptor. J. Neurosci. (1997) 17:5327–5333.
   PubMed Web of Science ®Google Scholar
• •The first report ever published on the coupling of CBI receptors to stimulation of cAMP formation.
   Google Scholar
• TVVITCHELL W, BROWN SAND MACKIE K: Cannabinoids inhibit N-and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol. (1997) 78:43–50.
   PubMed Web of Science ®Google Scholar
• SUGIURA T, KODAKA T, KONDO S et al.: Inhibition by 2-arachidonoylglycerol, a novel type of possible neuromodulator, of the depolarization-induced increase in intracellular free calcium in neuroblas-toma x glioma hybrid NG108-15 cells. Biochem. Biophys. Res. Commun. (1997) 233:207–210.
   PubMed Web of Science ®Google Scholar
• GEBREMEDHIN D, LANGE AR, CAMPBELL WB, HILLARDCJ, HARDER DR: Cannabinoid CBI receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am. J. Physiol (1999) 276:H2085–2093.
   PubMed Web of Science ®Google Scholar
• FIMIANI C, MATTOCKS D, CAVANI F et al.: Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release. Cell Signal. (1999) 11:189–193.
   PubMed Web of Science ®Google Scholar
• HILLARD CJ, MUTHIAN S, KEARN CS: Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett. (1999) 459:277–281.
   PubMed Web of Science ®Google Scholar
• JOHNSON DE, HEALD SL, DALLY RD, JANIS RA: Isolation, identification and synthesis of an endogenous arachi-donic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding. Prostaglandins Leukot. Essent. Fat t y Acids (1993) 48:429–437.
   PubMed Web of Science ®Google Scholar
• LIU J, GAO B, MIRSHAHI F et al: Functional CBI cannabi-noid receptors in human vascular endothelial cells. Biochem. j (2000) 346:835–840.
   PubMed Web of Science ®Google Scholar
• POLING JS, ROGAWSKI MA, SALEM N JR., VICINI S: Anandamide, an endogenous cannabinoid, inhibits Shaker-related voltage-gated K+ channels. Neurophar-macology (1996) 35:983–991.
   Google Scholar
• KISS Z: Anandamide stimulates phospholipase D activity in PC12 cells but not in NIH 313 fibroblasts. FEBS Lett. (1999) 447:209–212.
   PubMed Web of Science ®Google Scholar
• DE PETROCELLIS L, ORLANDO P, DI MARZO V: Anandamide, an endogenous cannabinomimetic substance, modulates rat brain protein kinase C in vitro. Biochem. Mol. Biol. Int. (1995) 36:1127–1133.
   PubMedGoogle Scholar
• VENANCE L, PIOMELLI D, GLOWINSKI J, GIAUME C: Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature (1995) 376:590–594.
   PubMed Web of Science ®Google Scholar
• BOGER DL, PATTERSON JE, GUAN X, CRAVATT BF, LERNER RA, GILULA NB: Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide. Proc. Natl. Acad. Sci. USA (1998) 95:4810–4815.
   PubMed Web of Science ®Google Scholar
• SCHMID HH, SCHMID PC, NATARAJAN V: The N-acylation-phosphodiesterase pathway and cell signalling. Chem. Phys. Lipids (1996) 80:133–142.
   PubMed Web of Science ®Google Scholar
• HANSEN HS, LAURITZEN L, MOESGAARD B, STRAND AM, HANSEN HH: Formation of N-acyl- phosphatidylethanolaminesandN-acetylethanolamines: proposed role in neurotox-icity. Biochem. Pharmacol. (1998) 55:719–725.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review on the metabolism and possible role in neuroprotection of endocannabinoids.
   Google Scholar
• DI MARZO V: Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. Life Sci. (1999) 65:645–655.
   PubMed Web of Science ®Google Scholar
• DI MARZO V, FONTANA A, CADAS H etaiFormation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 372:686–691.
   PubMed Web of Science ®Google Scholar
• ••The first report on the biosynthesis, release and inactivationof anandamide by neuronal cells.
   Google Scholar
• BISOGNO T, SEPE N, MELCK D, MAURELLI S, DE PETROCELLIS L, DI MARZO V: Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2 -arachidonoylglycer ol in mouse neuroblastoma cells. Biochem. J. (1997) 322:671-677. The first report on the biosynthesis, release and inactivation of cannabimimetic 2-AG by neuronal cells.
   Google Scholar
• SUGIURA T, KONDO S, SUKAGAWA A et al.: Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoyl-ethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Eur. J. Biochem. (1996) 240:53–62.
   Google Scholar
• •The first insight into the molecular mechanisms regulating anandamide biosynthesis.
   Google Scholar
• CADAS H, DI TOMASO E, PIOMELLI D: Occurrence andbiosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. j Neurosci. (1997) 17:1226–1242.
   PubMed Web of Science ®Google Scholar
• STELLA N, SCHWEITZER P, PIOMELLI D: A secondendogenous cannabinoid that modulates long-term potentiation. Nature (1997) 388:773–778.
   PubMed Web of Science ®Google Scholar
• BISOGNO T, MELCK D, DE PETROCELLIS L, DI MARZO V:Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin.j Neurochem. (1999) 72:2113–2119.
   PubMed Web of Science ®Google Scholar
• SCHMID HH: Pathways and mechanisms ofN-acylethanolamine biosynthesis: can anandamide be generated selectively? Chem. Phys. Lipids (2000) 108:71–87.
   PubMed Web of Science ®Google Scholar
• HILLARD CJ, JARRAHIAN A: The movement of N-arachidonoyl-ethanolamine (anandamide) across cellular membranes. Chem. Phys. Lipids (2000) 108:123–134.
   PubMed Web of Science ®Google Scholar
• ••An excellent, comprehensive and up-to-date review on theanandamide membrane transporter.
   Google Scholar
• DEUTSCH DG, GLASER ST, HOWELL JM et al.: The cellular uptake of anandamide is coupled to its breakdown by fatty acid amide hydrolase (FAAH. J Biol. Chem. (2001) in press.
   Google Scholar
• •First evidence that FAAH participates in anandamide transport across the membrane.
   Google Scholar
• DI MARZO V, BISOGNO T, SUGIURA T, MELCK D AND DEPETROCELLIS L: The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal-and basophil-like cells: connections with anandamide. Biochem. J. (1998) 331:15–19.
   PubMed Web of Science ®Google Scholar
• CRAVATT BF, GIANG DK, MAYFIELD SP, BOGER DL, LERNER RA, GILULA NB: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature (1996) 384:83–87.
   PubMed Web of Science ®Google Scholar
• ••Molecular characterisation of FAAH.
   Google Scholar
• UEDA N, KURAHASHI Y, YAMAMOTO S, TOKUNAGA T: Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. j Biol. Chem. (1995) 270:23823–23827.
   PubMed Web of Science ®Google Scholar
• •First partial purification of FAAH and demonstration that the enzyme can work also in reverse'.
   Google Scholar
• DI MARZO V, BISOGNO T, DE PETROCELLIS L et al: Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur.J. Biochem. (1999) 264:258–267.
   PubMedGoogle Scholar
• BELTRAMO M, STELLA N, CALIGNANO A et al: Functionalrole of high-affinity anandamide transport, as revealed by selective inhibition. Science (1997) 277:1094–1097.
   PubMed Web of Science ®Google Scholar
• •First report of an inhibitor of anandamide transport across the membrane.
   Google Scholar
• MACCARRONE M, BARI M, LORENZON T, BISOGNO T, DI MARZO V, FINAZZI-AGRO' A: Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J Biol. Chem. (2000) 275:13484–13492.
   PubMed Web of Science ®Google Scholar
• •First report that CBI receptors are positively linked to endocannabinoid uptake via NO.
   Google Scholar
• GIFFORD AN, BRUNEUS M, LIN S et al: Potentiation ofthe action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmityl-sulphonyl fluoride (AM 374). Eur. J. Pharmacol. (1999) 383:9–14.
   PubMed Web of Science ®Google Scholar
• MARTIN BR, BELETSKAYA I, PATRICK G et al: Cannabi-noid properties of methylfluorophosphonate analogs. Pharmacol Exp. Ther. (2000) 294:1209–1218.
   PubMed Web of Science ®Google Scholar
• BELTRAMO M, PIOMELLI D: Carrier-mediated transportand enzymatic hydrolysis of the endogenous cannabi-noid 2-arachidonylglycerol. Neuroreport (2000) 11:1231–1235.
   PubMed Web of Science ®Google Scholar
• BISOGNO T, MACCARRONE M, DE PETROCELLIS L et al:On the uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. (2001) Eur. J. Biochem. In press.
   Google Scholar
• MACCARRONE M, VAN DER STELT M, ROSSI A, VELDINKGA, VLIEGENTHART JF, FINAZZI-AGRO' A: Anandamide hydrolysis by human cells in culture and brain. j Chem. (1998) 273:32332–32339.
   Web of Science ®Google Scholar
• •First evidence for the effect of NO on the anandamide membrane transporter.
   Google Scholar
• UEDA N, PUFFENBARGER RA, YAMAMOTO S, DEUTSCH DG: The fatty acid amide hydrolase. Chem. Phys. Lipids (2000) 108:107–121.
   PubMed Web of Science ®Google Scholar
• ••An excellent, comprehensive and up-to-date review onFAAH.
   Google Scholar
• ARREAZA G, DEUTSCH DG: Deletion of a proline-richregion and a transmembrane domain in fatty acid amide hydrolase. FEBS Lett. (1999) 454:57–60.
   PubMed Web of Science ®Google Scholar
• PATRICELLI MP, CRAVATT BF: Clarifying the catalyticroles of conserved residues in the amidase signature family. J Biol. Chem. (2000) 275:19177–19184.
   PubMed Web of Science ®Google Scholar
• DINH TP, LESLIE F, ZHOU QY, PIOMELLI D: Molecular characterization of a rat brain monoacylglycerol lipase that participates in the hydrolysis of the endocannabinoid 2-arachidonoylglycerol. Soc. Neurosci. (2000) 26:2164, 813.8.
   Google Scholar
• KOZAK KR, ROWLINSON SW, MARNETT LJ: Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Chem. (2000) 275:33744–33749.
   Web of Science ®Google Scholar
• •First evidence that 2-AG can be oxidised by COX-2 in intact cells.
   Google Scholar
• YU M, IVES D, RAMESHA CS: Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2./ Biol. Chem. (1997) 272:21181–21186.
   PubMed Web of Science ®Google Scholar
• EDGEMOND WS, HILLARD CJ, FALCK JR, KEARN CS, CAMPBELL WB: Human platelets and polymorphonu-clear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affini-ties for cannabinoid receptors and pathways of inacti-vation. Mol. Pharmacol (1998) 54:180–188.
   PubMed Web of Science ®Google Scholar
• •First evidence that anandamide can be oxidised by lipoxy-genases in intact cells.
   Google Scholar
• UEDA N, YAMANAKA K, TERASAWA Y, YAMAMOTO S: An acid amidase hydrolyzing anandamide as an endoge-nous ligand for cannabinoid receptors. FEBS Lett. (1999) 454:267–270.
   PubMed Web of Science ®Google Scholar
• MACCARRONE M, DI MARZO V, BARI M et al.: lipopoly-saccharide down-regulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Submitted.
   Google Scholar
• ADAMS TB, RYAN W, SINGER M et al: Evaluation of cannabinoid receptor binding and in vivoactivities for anandamide analogs. J. Pharmacol. Exp. Ther. (1995) 273:1172–1181.
   PubMed Web of Science ®Google Scholar
• HILLARD CJ, MANNA S, GREENBERG MJ et al: Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CBI). J. Pharmacol. Exp. Ther. (1999) 289:1427–1433.
   PubMed Web of Science ®Google Scholar
• •First report of CB1-selective ligands.
   Google Scholar
• BISOGNO T, MELCK D, BOBROV MY et al: N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. (2000) 351:817–824.
   Google Scholar
• KHANOLKAR AD, MAKRIYANNIS A: Structure-activity relationships of anandamide, an endogenous cannabi-noid ligand. Life Sci. (1999) 65:607–616.
   PubMed Web of Science ®Google Scholar
• MARTIN BR, MECHOULAM R, RAZDAN RK: Discovery and characterization of endogenous cannabinoids. Life Sci. (1999) 65:573–595.
   PubMed Web of Science ®Google Scholar
• DE PETROCELLIS L, BISOGNO T, DAVIS JB, PERTWEE RG, DI MARZO V: Overlap between the ligand recognition properties of the anandamide transporter and the V1R1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. (2000) 483:52–56.
   PubMed Web of Science ®Google Scholar
• •First report of inhibitors of the anandamide membrane transporter selective vs. VR1 receptors.
   Google Scholar
• DI MARZO V, BISOGNO T, DE PETROCELLIS L et al: Highly selective CB1 cannabinoid receptor ligands and novel CBI/VR1 vanilloid receptor 'hybrid' ligands. Biochem. Biophys. Res. Commun. (2001) 281:444–451.
   PubMed Web of Science ®Google Scholar
• •First report of a CBI receptor ligand extremely selective vs. both CB2 and VR1 receptors.
   Google Scholar
• ROSS RA, BROCKIE HC, STEVENSON LA et al.: Agonist-inverse agonist characterization at CBI. and CB2 cannabinoid receptors of L759633, L759656 and AlV1630. Br. J. Pharmacol. (1999) 126:665–672.
   Google Scholar
• HUFFMAN JW: The search for selective ligands for the CB2 receptor. Curr. Pharm. Des. (2000) 6:1323–1337.
   PubMed Web of Science ®Google Scholar
• TREMBLAY N, ROCHETTE C, SAWYER N et al.: New class of potent ligands for the human peripheral cannabi-noid receptor. Bioorg. Med. Chem. Lett. (1996) 6:2263–2268.
   Web of Science ®Google Scholar
• BAKER D, PRYCE G, CROXFORD JL et al: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 404:84–87.
   PubMed Web of Science ®Google Scholar
• ••First accurate demonstration that cannabinoids can alleviatesigns of MS in an animal model.
   Google Scholar
• HANUS L, BREUER A, TCHILIBON S et al.: HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc. Natl Acad. Sci. USA (1999) 96:14228–14233.
   PubMed Web of Science ®Google Scholar
• •Intriguing suggestion that CB2 receptors may participate in some cardiovascular and gastrointestinal functions.
   Google Scholar
• BARTH F, RINALDI-CARMONA M: The development of cannabinoid antagonists. Curr. Med. Chem. (1999) 6:745–755.
   PubMed Web of Science ®Google Scholar
• RINALDI-CARMONA M, BARTH F, HEAULME M et al.: 5R141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350:240–244.
   PubMed Web of Science ®Google Scholar
• ••First development of a selective CBI receptor antagonist.
   Google Scholar
• GATLEY SJ, GIFFORD AN, VOLKOW ND, LAN R AND MAKRIYANNIS A: 1231-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabi-noid CBI receptors. Eur. j Pharmacol. (1996) 307, 331–338.
   PubMed Web of Science ®Google Scholar
• FELDER CC, JOYCE KE, BRILEY EM et al.: LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther. (1998) 284:291–297.
   PubMed Web of Science ®Google Scholar
• CHAYTOR AT, MARTIN PE, EVANS WH, RANDALL MD, GRIFFITH TM: The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol. (1999) 520:539–550.
   PubMed Web of Science ®Google Scholar
• RINALDI-CARMONA M, BARTH F, MILLAN J et al.: SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. (1998) 284:644–650.
   PubMed Web of Science ®Google Scholar
• ••First development of a selective CB2 receptor antagonist.
   Google Scholar
• BAKER D, PRYCE G, CROXFORD JL et al: Endocannabi-noids control spasticity in a multiple sclerosis model. FASEB (2001) 15:300–302
   PubMed Web of Science ®Google Scholar
• ••First demonstration that endocannabinoids tonicallyalleviate spasticity.
   Google Scholar
• JARRAHIAN A, MANNA S, EDGEMOND WS, CAMPBELL WB, HILLARD CJ: Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. J Neurochem. (2000) 74:2597–2606.
   PubMed Web of Science ®Google Scholar
• DI MARZO V, BISOGNO T, MELCK D et al.: Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett. (1998) 436:449–454.
   PubMed Web of Science ®Google Scholar
• ••First evidence of the capability of a vanilloid receptor ligandto interact with several targets of the endocannabinoid system.
   Google Scholar
• ZYGMUNT PM, CHUANG H, MOVAHED P, JULIUS D AND HOGESTATT ED: The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur. j Pharmacol. (2000) 396:39–42.
   PubMed Web of Science ®Google Scholar
• SMART D, JERMAN JC: Anandamide: an endogenous activator of the vanilloid receptor. Trends Pharmacol. Sci. (2000) 21:134.
   PubMed Web of Science ®Google Scholar
• KOUTEK B, PRESTVVICH GD, HOWLETT AC et al.: Inhibi-tors of arachidonoyl ethanolamide hydrolysis. J. Biol. Chem. (1994) 269:22937–22940.
   PubMed Web of Science ®Google Scholar
• •First selective inhibitors of FAAH.
   Google Scholar
• DE PETROCELLIS L, MELCK D, UEDA N et al: Novel inhibitors of brain, neuronal and basophilic anandamide amidohydrolase. Biochem. Biophys. Res. Commun. (1997) 231:82–88.
   PubMed Web of Science ®Google Scholar
• DEUTSCH DG, OMEIR R, ARREAZA G et al: Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem. Pharmacol. (1997) 53:255–260.
   PubMed Web of Science ®Google Scholar
• EDGEMOND WS, GREENBERG MJ, MCGINLEY PJ, MUTHIAN S, CAMPBELL WB, HILLARD CJ: Synthesis and characterization of diazomethylarachidonyl ketone: anirreversibleinhibitorofN-arachidonylethanolamine amidohydrolase. J. Pharmacol. Exp. Ther. (1998) 286:184–190.
   PubMed Web of Science ®Google Scholar
• DE PETROCELLIS L, MELCK D, UEDA N et al: Brain and peripheral anandamide amidohydrolase and its inhibition by synthetic arachidonate analogues. Adv. Exp. Med. Biol. (1997) 433:259–263.
   PubMed Web of Science ®Google Scholar
• BISOGNO T, MELCK D, DE PETROCELLIS L et al.: Arachi-donoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. (1998) 248:515–522.
   Google Scholar
• •The first reversible inhibitors of FAAH that do not interact with either CBI receptors or phospholipase A2.
   Google Scholar
• DEUTSCH DG, UN S, HILL WA et al: Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem. Biophys. Res. Commun. (1997) 231:217–221.
   PubMed Web of Science ®Google Scholar
• •The first irreversible inhibitors of FAAH that do not interact with CBI receptors.
   Google Scholar
• BEN-SHABAT S, FRIDE E, SHESKIN T et al.: An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. j Pharmacol. (1998) 353:23–31.
   PubMed Web of Science ®Google Scholar
• •First demonstration of 'entourage' effects for the action of endocannabinoids.
   Google Scholar
• MALFAIT AM, GALLILY R, SUMARIWALLA PF et al.: The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA (2000) 97:9561–9566.
   PubMed Web of Science ®Google Scholar
• RAKHSHAN F, DAY TA, BLAKELY RD, BARKER EL: Carrier-mediated uptake of the endogenous cannabi-noid anandamide in RBL-2H3 cells. J. Pharmacol. Exp. Ther. (2000) 292:960–967.
   PubMed Web of Science ®Google Scholar
• BURSTEIN SH: The cannabinoid acids: nonpsychoac-tive derivatives with therapeutic potential. Pharmacol. Ther. (1999) 82:87–96.
   PubMed Web of Science ®Google Scholar
• DI MARZO V, HILL MP, BISOGNO T, CROSSMAN AR, BROTCHIE JM: Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB (2000) 14:1432–1438.
   PubMed Web of Science ®Google Scholar
• •First correlation between endocannabinoid levels and signs of Parkinson's in an animal model.
   Google Scholar